1. Home
  2. BAFN vs HBIO Comparison

BAFN vs HBIO Comparison

Compare BAFN & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BayFirst Financial Corp.

BAFN

BayFirst Financial Corp.

HOLD

Current Price

$6.25

Market Cap

26.6M

Sector

Finance

ML Signal

HOLD

Logo Harvard Bioscience Inc.

HBIO

Harvard Bioscience Inc.

HOLD

Current Price

$5.52

Market Cap

24.9M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
BAFN
HBIO
Founded
1999
1901
Country
United States
United States
Employees
N/A
339
Industry
Savings Institutions
Biotechnology: Laboratory Analytical Instruments
Sector
Finance
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
26.6M
24.9M
IPO Year
2021
2000

Fundamental Metrics

Financial Performance
Metric
BAFN
HBIO
Price
$6.25
$5.52
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$18.00
AVG Volume (30 Days)
73.4K
28.2K
Earning Date
04-30-2026
05-12-2026
Dividend Yield
1.00%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$116,176,000.00
Revenue This Year
N/A
$4.77
Revenue Next Year
N/A
$8.55
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.80
$0.28
52 Week High
$16.35
$7.50

Technical Indicators

Market Signals
Indicator
BAFN
HBIO
Relative Strength Index (RSI) 40.77 51.92
Support Level $5.94 $0.47
Resistance Level $7.08 $7.25
Average True Range (ATR) 0.56 0.46
MACD -0.13 -0.19
Stochastic Oscillator 16.84 38.47

Price Performance

Historical Comparison
BAFN
HBIO

About BAFN BayFirst Financial Corp.

BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.

About HBIO Harvard Bioscience Inc.

Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.

Share on Social Networks: